Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment

NCT04838860 is registered in ClinicalTrials.gov with RECORDATI GROUP as lead sponsor.

NCT NCT04838860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04838860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Intrapatient Siltuximab Dose Escalation in Patients With Idiopathic Multicentric Castleman Disease That Has Progressed After Prior Siltuximab Treatment
Lead sponsor
RECORDATI GROUP
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2021
Completion date
April 1, 2021
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic multicentric castleman's disease